Skip to content
lifestyle.longislandreport.org
Animals
Auto
Beauty & Style
Business News
Entertainment
Food
Health
Home & Family
Podcasts
Tech
Travel
Author:
Mabwell (Shanghai) Bioscience Co., Ltd.
Mabwell Announces Latest Clinical Data on 9MW2821 to Be Presented at 2026 ASCO Annual Meeting as Oral and Poster Presentations
May 21, 2026
2026 ESMO GC | Mabwell to Present Latest Clinical Data on 9MW2821 for Cervical Cancer in Oral and Poster Presentations
April 30, 2026
Mabwell Initiates Phase III Clinical Study of its Nectin-4-Targeting ADC 9MW2821 for the Treatment of Triple-Negative Breast Cancer
April 23, 2026
2026 ASCO | Mabwell to Present Latest Clinical Data on 9MW2821 Combined with Toripalimab for Urothelial Carcinoma in Oral and Poster Presentations
April 23, 2026
Case Report of Mabwell’s Nectin-4 targeting ADC (9MW2821) in Cervical Cancer Published in The New England Journal of Medicine
April 21, 2026
Mabwell Passes On-site GMP Inspection by Regulatory Authority of PIC/S Member Country (Jordan) for the First Time
April 20, 2026
Mabwell Establishes a Licensing and Commercialization Agreement for Denosumab Biosimilars in Malaysian Market
April 16, 2026
Global First | NMPA Accepts IND Application for Mabwell’s Innovative LILRB4/CD3 TCE Bispecific Antibody 6MW5311
April 15, 2026
Mabwell Announces Acceptance of Supplemental Biologics License Application by NMPA for MAIWEIJIAN (Denosumab)
April 15, 2026
SST001, an α-syn PET tracer from Mabwell’s incubated company SynuSight Biotech, received NMPA approval to initiate a clinical trial
April 14, 2026
1
2
Next Page
→